This project identified key genetic alterations, including mutations in genes such as TP53, PTEN, EGFR, and NF1. These findings have been instrumental in elucidating the molecular mechanisms underpinning GBM, paving the way for targeted therapies and personalized medicine approaches in treating this challenging brain tumor [3]. The gene discussed is EGFR; the disease is glioblastoma.